ANAL CANAL CLOACOGENIC CARCINOMA
Clinical trials for ANAL CANAL CLOACOGENIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ANAL CANAL CLOACOGENIC CARCINOMA trials appear
Sign up with your email to follow new studies for ANAL CANAL CLOACOGENIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Major trial tests if boosting immune system can stop anal Cancer's return
Disease control OngoingThis large, late-stage trial is testing whether adding the immunotherapy drug nivolumab after standard chemoradiation treatment can help prevent cancer from returning in patients with high-risk anal cancer. The study involves 344 adults who have completed initial treatment. Parti…
Matched conditions: ANAL CANAL CLOACOGENIC CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 03:51 UTC
-
Study aims to tame anal cancer with less harsh treatment
Disease control OngoingThis study is testing whether a lower dose of chemotherapy combined with radiation works as well as the standard, stronger dose for treating early-stage anal cancer. It involves 252 adults with early-stage disease who have not spread to lymph nodes. The main goal is to see if the…
Matched conditions: ANAL CANAL CLOACOGENIC CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Major trial aims to boost survival for advanced anal cancer
Disease control OngoingThis large, late-stage trial is testing whether adding an immunotherapy drug (nivolumab) to standard chemotherapy works better than chemotherapy alone for anal cancer that has spread. It will enroll about 205 adults whose cancer cannot be cured by surgery or radiation. The main g…
Matched conditions: ANAL CANAL CLOACOGENIC CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC